Fasting in combination with chemotherapy has already been shown to kill cancer cells, but a pair of new studies in mice suggests that a less-toxic class of drugs combined with fasting may kill breast, colorectal and lung cancer cells equally well.
If shown to work in humans, this combination could replace chemotherapy and make fasting a potent component of a long-term strategy to treat cancer, according to senior author Valter Longo of USC.
Human clinical trials in the United States and Europe are already studying the effectiveness and safety of Longo's strategy of cyclic fasting during cancer treatment.
Published by the journal Oncotarget on March 30, the studies suggest that a low-toxicity drug combined with fasting, or a diet that mimics the effects of fasting, could be an alternative to chemotherapy. The studies are part of a multinational collaboration with the laboratories of Alessio Nencioni at University of Genova and of Lizzia Raffaghello at the G. Gaslini Institute in Italy.
"Like every other cell, cancer cells need energy to survive and keep growing. But cancer cells are fairly inflexible about how they produce that energy, which gives us a way to target them," said Longo, Edna M. Jones Professor of Biogerontology at the USC Davis School of Gerontology and director of the USC Longevity Institute. Longo has a joint appointment at the USC Dornsife College of Letters, Arts and Sciences.
Cancer cells rely heavily on glucose (sugar) from food for energy—they're on overdrive, burning much more glucose than a regular cell to fuel their rapid growth. The phenomenon is called the Warburg effect, named after the German physician who first described it nearly 100 years ago. As such, cancer cells are much more vulnerable to any interruption in supply.
Deprived of glucose, cancer cells rely on an emergency backup—using a type of enzyme called a kinase to continue their growth-related activities.
Longo and his team and collaborators discovered that this metabolic shift by cancer cells causes them to generate toxic-free radicals, which ultimately kills them. In addition, the kinase pathway for generating energy can be blocked by kinase inhibitors, further choking off cancer cells' ability to generate energy. Kinase inhibitors are already approved by the U.S. Food and Drug Administration as a cancer treatment, opening the door to using them and fasting as a one-two punch to knock out cancer.
"However, kinase inhibitors, though much less toxic than chemotherapy, can still be toxic to many cell types. Fasting makes them more effective, meaning that patients would have to use them for less time to achieve the same results," Longo said. "Although we have not yet tested this, we anticipate that fasting will also reduce the toxicity of kinase inhibitors as it reduces that of chemotherapy to normal cells."
Explore further: Fasting triggers stem cell regeneration of damaged, old immune system
More information: Both studies can be found online at: http://ift.tt/V8ox7X ue&op=view&path[]=79
Medical Xpress on facebook
Related Stories
Fasting makes brain tumors more vulnerable to radiation therapy
A new study from USC researchers is the first to show that controlled fasting improves the effectiveness of radiation therapy in cancer treatments, extending life expectancy in mice with aggressive brain tumors.
Fasting triggers stem cell regeneration of damaged, old immune system
In the first evidence of a natural intervention triggering stem cell-based regeneration of an organ or system, a study in the June 5 issue of the Cell Press journal Cell Stem Cell shows that cycles of prolonged fasting not on ...
Short fasting cycles work as well as chemotherapy in mice
Man may not live by bread alone, but cancer in animals appears less resilient, judging by a study that found chemotherapy drugs work better when combined with cycles of short, severe fasting.
Nano packages for anti-cancer drug delivery
Cancer stem cells are resistant to chemotherapy and consequently tend to remain in the body even after a course of treatment has finished, where they can often trigger cancer recurrence or metastasis. A new ...
Combining the old and new to kill cancer cells
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr. Jit ...
Recommended for you
Low vitamin D linked to worse prognosis in type of non-Hodgkin lymphoma
A new study found that people with lower vitamin D levels prior to treatment for follicular lymphoma succumb to the disease or face relapse earlier than patients with sufficient vitamin D levels in their blood.
Panel predicts whether rare leukemia will respond to treatment
Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers ...
New drug stalls estrogen receptor-positive cancer cell growth and shrinks tumors
An experimental drug rapidly shrinks most tumors in a mouse model of human breast cancer, researchers report in the Proceedings of the National Academy of Sciences. When mice were treated with the experi ...
To stop cancer: Block its messages
The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions ...
Team identifies new gene involved in hereditary neuroendocrine tumors
Researchers in the Hereditary Endocrine Cancer Group of the Spanish National Cancer Research Centre (CNIO)—led by Alberto Cascón and Mercedes Robledo—have described the presence of mutations in the MDH2 ...
Early stage NSCLC patients with low tumor metabolic activity have longer survival
Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer (NSCLC) is associated with increased overall survival and a longer ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Fasting in combination with chemotherapy has already been shown to kill cancer cells, but a pair of new studies in mice suggests that a less-toxic class of drugs combined with fasting may kill breast, colorectal and lung cancer cells equally well.
If shown to work in humans, this combination could replace chemotherapy and make fasting a potent component of a long-term strategy to treat cancer, according to senior author Valter Longo of USC.
Human clinical trials in the United States and Europe are already studying the effectiveness and safety of Longo's strategy of cyclic fasting during cancer treatment.
Published by the journal Oncotarget on March 30, the studies suggest that a low-toxicity drug combined with fasting, or a diet that mimics the effects of fasting, could be an alternative to chemotherapy. The studies are part of a multinational collaboration with the laboratories of Alessio Nencioni at University of Genova and of Lizzia Raffaghello at the G. Gaslini Institute in Italy.
"Like every other cell, cancer cells need energy to survive and keep growing. But cancer cells are fairly inflexible about how they produce that energy, which gives us a way to target them," said Longo, Edna M. Jones Professor of Biogerontology at the USC Davis School of Gerontology and director of the USC Longevity Institute. Longo has a joint appointment at the USC Dornsife College of Letters, Arts and Sciences.
Cancer cells rely heavily on glucose (sugar) from food for energy—they're on overdrive, burning much more glucose than a regular cell to fuel their rapid growth. The phenomenon is called the Warburg effect, named after the German physician who first described it nearly 100 years ago. As such, cancer cells are much more vulnerable to any interruption in supply.
Deprived of glucose, cancer cells rely on an emergency backup—using a type of enzyme called a kinase to continue their growth-related activities.
Longo and his team and collaborators discovered that this metabolic shift by cancer cells causes them to generate toxic-free radicals, which ultimately kills them. In addition, the kinase pathway for generating energy can be blocked by kinase inhibitors, further choking off cancer cells' ability to generate energy. Kinase inhibitors are already approved by the U.S. Food and Drug Administration as a cancer treatment, opening the door to using them and fasting as a one-two punch to knock out cancer.
"However, kinase inhibitors, though much less toxic than chemotherapy, can still be toxic to many cell types. Fasting makes them more effective, meaning that patients would have to use them for less time to achieve the same results," Longo said. "Although we have not yet tested this, we anticipate that fasting will also reduce the toxicity of kinase inhibitors as it reduces that of chemotherapy to normal cells."
Explore further: Fasting triggers stem cell regeneration of damaged, old immune system
More information: Both studies can be found online at: http://ift.tt/V8ox7X ue&op=view&path[]=79
Medical Xpress on facebook
Related Stories
Fasting makes brain tumors more vulnerable to radiation therapy
A new study from USC researchers is the first to show that controlled fasting improves the effectiveness of radiation therapy in cancer treatments, extending life expectancy in mice with aggressive brain tumors.
Fasting triggers stem cell regeneration of damaged, old immune system
In the first evidence of a natural intervention triggering stem cell-based regeneration of an organ or system, a study in the June 5 issue of the Cell Press journal Cell Stem Cell shows that cycles of prolonged fasting not on ...
Short fasting cycles work as well as chemotherapy in mice
Man may not live by bread alone, but cancer in animals appears less resilient, judging by a study that found chemotherapy drugs work better when combined with cycles of short, severe fasting.
Nano packages for anti-cancer drug delivery
Cancer stem cells are resistant to chemotherapy and consequently tend to remain in the body even after a course of treatment has finished, where they can often trigger cancer recurrence or metastasis. A new ...
Combining the old and new to kill cancer cells
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr. Jit ...
Recommended for you
Low vitamin D linked to worse prognosis in type of non-Hodgkin lymphoma
A new study found that people with lower vitamin D levels prior to treatment for follicular lymphoma succumb to the disease or face relapse earlier than patients with sufficient vitamin D levels in their blood.
Panel predicts whether rare leukemia will respond to treatment
Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers ...
New drug stalls estrogen receptor-positive cancer cell growth and shrinks tumors
An experimental drug rapidly shrinks most tumors in a mouse model of human breast cancer, researchers report in the Proceedings of the National Academy of Sciences. When mice were treated with the experi ...
To stop cancer: Block its messages
The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions ...
Team identifies new gene involved in hereditary neuroendocrine tumors
Researchers in the Hereditary Endocrine Cancer Group of the Spanish National Cancer Research Centre (CNIO)—led by Alberto Cascón and Mercedes Robledo—have described the presence of mutations in the MDH2 ...
Early stage NSCLC patients with low tumor metabolic activity have longer survival
Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer (NSCLC) is associated with increased overall survival and a longer ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment